The performance of companies tied to Sildenafil's legacy presents a intricate investment landscape. While the initial surge generated substantial gains, generic alternatives have significantly eroded market share . Investing in connected pharmaceutical companies now requires a discerning assessment of intellectual property safeguards, evolving medi